Ryvu Therapeutics S.A. (RVU.WA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-1415.4%

-PLN 217.04

vs PLN 16.50 price

Levered DCF

-PLN 234.93

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-1.05

Distress zone

Rating

D+

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-6.19×	-7.99×	-14.05×	-10.78×	-14.15×	-26.03×	-20×	-7,797.1×
P/B	11.64×	6.19×	4.98×	2.63×	6.94×	3.69×	6×	4.34×
P/S	10.06×	11.42×	27.61×	23.27×	100.09×	53.51×	16.88×	10.78×
EV / EBITDA	-5.67×	-8.32×	-15.26×	-12.33×	-15.79×	-38.95×	-18.36×	-46.84×
Gross margin	-188.0%	74.9%	62.5%	55.1%	-22.7%	43.1%	-117.8%	61.6%
Operating margin	-196.2%	-156.6%	-215.4%	-202.1%	-927.8%	-231.6%	-106.0%	-17.6%
Net margin	-162.6%	-142.9%	-196.6%	-215.9%	-706.9%	-205.6%	-84.6%	-0.1%
Current ratio	2.26×	2.52×	3.99×	8.21×	2.88×	5.1×	2.94×	4.87×
Debt / equity	1.33×	0.52×	0×	0.01×	0.03×	0.03×	0.08×	0.07×
Interest coverage	-13.88×	-32.06×	-1,040.7×	-72.01×	-234.8×	-92.14×	-113.33×	-46.7×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-188.0%	-77.4%	-35.5%	-24.4%	-49.0%	-14.2%	-30.1%	-0.1%
Return on invested capital	-74.8%	-44.9%	-30.2%	-18.2%	-53.1%	-13.5%	-29.0%	-0.6%
Return on assets	-45.1%	-29.4%	-22.8%	-17.6%	-34.6%	-10.7%	-19.7%	-0.0%
Free cash flow yield	-18.8%	-15.2%	-6.8%	1.3%	-6.2%	-5.4%	-5.8%	-7.2%
Earnings yield	-16.2%	-12.5%	-7.1%	-9.3%	-7.1%	-3.8%	-5.0%	-0.0%
Enterprise value	PLN 638.7M	PLN 805.6M	PLN 1.2B	PLN 803.8M	PLN 1B	PLN 696.1M	PLN 655.8M	PLN 735.6M
Net debt / EBITDA	-0.11×	0.87×	0.7×	1.52×	1.19×	7.21×	1.76×	6.17×
Cash conversion cycle (days)	88	-460	-366	-179	124	-3	83	-80